You are here
Home > Dilution > Hydralazine 


The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.    PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Usual Diluents


Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]

[0 to 20 mg] [50 ml] [30 min]
[21 to 40 mg] [100 ml] [30 min]
[>40 mg] [250 ml] [60 min or longer]

Monitor BP q5min during initial infusion.

Stability / Miscellaneous

Manufacturer recommends IM or IV push.

Usual dosage: 10 to 40 mg IV q4-6h prn. May be given q20-30 minutes (until adequate response) for the treatment of severe hypertension. IV push (rate): 10 mg/min.

Label: Do not refrigerate. Stability: 24 hours room temperature.

When there is urgent need, therapy in the hospitalized patient may be initiated intramuscularly or as a rapid intravenous bolus injection directly into the vein. Hydralazine hydrochloride injection should be used only when the drug cannot be given orally. The usual dose is 20-40 mg, repeated as necessary.

Certain patients (especially those with marked renal damage) may require a lower dose. Blood pressure should be checked frequently. It may begin to fall within a few minutes after injection, with the average maximal decrease occurring in 10-80 minutes. In cases where there has been increased intracranial pressure, lowering the blood pressure may increase cerebral ischemia. Most patients can be transferred to oral hydralazine hydrochloride within 24-48 hours.

The product should be used immediately after the vial is opened. It should not be added to infusion solutions. Hydralazine hydrochloride injection may discolor upon contact with metal; discolored solutions should be discarded.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Source: [package insert]